InnovoTex Inc.
InnovoTex Inc.
  • HOME
  • SCIENCE
  • PIPELINE
  • About
  • NEWS
  • Contact
  • More
    • HOME
    • SCIENCE
    • PIPELINE
    • About
    • NEWS
    • Contact
  • HOME
  • SCIENCE
  • PIPELINE
  • About
  • NEWS
  • Contact

INNOVOTEX

Revolutionizing macrocycle chemistry 

for the treatment of aggressive cancers.

Our Mission

Pioneering macrocycle drug conjugates

INNOVOTEX is developing its proprietary platform of macrocycle drug conjugates (MDCs) as a new class ​
of antigen independent, tumor-targeting therapies to facilitate enhanced intracellular uptake.

SCIENCE

transforming the treatment paradigm

Advanced Technology

>95% Tumor Growth Inhibition

>95% Tumor Growth Inhibition

Clinically validated macrocycle functions as a delivery vector by preferentially localizing to tumor cells. Optimized payload targets the cancer ribosome to target wt p53.

>95% Tumor Growth Inhibition

>95% Tumor Growth Inhibition

>95% Tumor Growth Inhibition

NOVO-111 induces significant tumor regression and increases survival in aggressive platinum-resistant cancers.

42-Fold Increase in Potency

>95% Tumor Growth Inhibition

42-Fold Increase in Potency

More potent than Standard of Care in platinum-resistant cancers.

latest news

INNOVOTEX to present Breakthrough Data at the American Association of Cancer Research Annual Meeting!

NEWS

Copyright © 2024 INNOVOTEX Inc. - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept